Campbell & CO Investment Adviser LLC Acquires New Position in Omnicell, Inc. $OMCL

Key Points

• Campbell & CO Investment Adviser LLC acquired 63,921 shares of Omnicell, Inc., valued at approximately $2.2 million, representing about 0.14% of the company's stock.
• Recent analyst upgrades for Omnicell include Wells Fargo raising the price target from $37.00 to $40.00, indicating a positive outlook for the stock.
• Omnicell reported an EPS of $0.45 for the last quarter, exceeding analysts' expectations and showing a 5.0% increase in revenue year-over-year.

Campbell & CO Investment Adviser LLC purchased a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 63,921 shares of the company's stock, valued at approximately $2,235,000. Campbell & CO Investment Adviser LLC owned approximately 0.14% of Omnicell at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Johnson Financial Group Inc. purchased a new position in Omnicell during the fourth quarter worth about $37,000. Point72 Hong Kong Ltd purchased a new position in Omnicell during the fourth quarter worth about $101,000. Corton Capital Inc. purchased a new position in Omnicell during the fourth quarter worth about $208,000. Caption Management LLC purchased a new position in Omnicell during the fourth quarter worth about $223,000. Finally, AlphaQuest LLC raised its stake in Omnicell by 79.0% during the first quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock worth $224,000 after purchasing an additional 2,824 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Trading Down 2.1%

Shares of Omnicell stock traded down $0.69 on Friday, reaching $32.59. The company had a trading volume of 595,171 shares, compared to its average volume of 577,128. The firm's 50 day moving average price is $30.07 and its two-hundred day moving average price is $31.56. The firm has a market cap of $1.50 billion, a PE ratio of 65.18, a PEG ratio of 7.12 and a beta of 0.78. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business's revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Sell-side analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Benchmark reduced their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company lifted their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Piper Sandler reduced their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Finally, Bank of America boosted their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.